Page 1 | Search Results | Blood Advances | American Society of Hematology

1-20 of 39

Sort by

Sort Order Select

Journal Articles

Multicenter analysis of geriatric fitness and real-world outcomes in older patients with classical Hodgkin lymphoma

Blood Adv (2021) 5 (18): 3623–3632.

https://doi.org/10.1182/bloodadvances.2021004645

Published: 2021

Includes: Supplemental data

Journal Articles

Toxicities of high-dose chemotherapy and autologous hematopoietic cell transplantation in older patients with lymphoma

Parastoo B. Dahi, Jasme Lee, Sean M. Devlin, Josel Ruiz, Molly Maloy, Carlos Rondon-Clavo, Erica Petrlik, Roni Tamari, Gunjan Shah, Michael Scordo, Matthew J. Matasar, Paul A. Hamlin, Esperanza Papadopoulos, Ann A. Jakubowski, Miguel-Angel Perales, Craig H. Moskowitz, Craig S. Sauter, Sergio A. Giralt

Blood Adv (2021) 5 (12): 2608–2618.

https://doi.org/10.1182/bloodadvances.2020004167

Published: 2021

Includes: Supplemental data

Journal Articles

Impact of R-CHOP dose intensity on survival outcomes in diffuse large B-cell lymphoma: a systematic review

Edward J. Bataillard, Chan Yoon Cheah, Matthew J. Maurer, Arushi Khurana, Toby A. Eyre, Tarec Christoffer El-Galaly

Blood Adv (2021) 5 (9): 2426–2437.

https://doi.org/10.1182/bloodadvances.2021004665

Published: 2021

Includes: Supplemental data

Journal Articles

Infection-related morbidity and mortality among older patients with DLBCL treated with full- or attenuated-dose R-CHOP

Toby A. Eyre, William Wilson, Amy A. Kirkwood, Julia Wolf, Catherine Hildyard, Hannah Plaschkes, John Griffith, Paul Fields, Arief Gunawan, Rebecca Oliver, Stephen Booth, Jaimal Kothari, Christopher P. Fox, Nicolas Martinez-Calle, Andrew McMillan, Mark Bishton, Graham P. Collins, Chris S. R. Hatton

Blood Adv (2021) 5 (8): 2229–2236.

https://doi.org/10.1182/bloodadvances.2021004286

Published: 2021

Includes: Supplemental data

Journal Articles

Outcomes of older patients with follicular lymphoma using individual data from 5922 patients in 18 randomized controlled trials

Blood Adv (2021) 5 (6): 1737–1745.

https://doi.org/10.1182/bloodadvances.2020002724

Published: 2021

Journal Articles

Older adults with newly diagnosed high-risk/secondary AML who achieved remission with CPX-351: phase 3 post hoc analyses

Tara L. Lin, David A. Rizzieri, Daniel H. Ryan, Gary J. Schiller, Jonathan E. Kolitz, Geoffrey L. Uy, Donna E. Hogge, Scott R. Solomon, Matthew J. Wieduwilt, Robert J. Ryan, Stefan Faderl, Jorge E. Cortes, Jeffrey E. Lancet

Blood Adv (2021) 5 (6): 1719–1728.

https://doi.org/10.1182/bloodadvances.2020003510

Published: 2021

Includes: Supplemental data

Journal Articles

Measurable residual disease in elderly acute myeloid leukemia: results from the PETHEMA-FLUGAZA phase 3 clinical trial

Blood Adv (2021) 5 (3): 760–770.

https://doi.org/10.1182/bloodadvances.2020003195

Published: 2021

Includes: Supplemental data

Journal Articles

Primary human herpesvirus 8–negative effusion-based lymphoma: a large B-cell lymphoma with favorable prognosis

Daisuke Kaji, Yasunori Ota, Yasuharu Sato, Koji Nagafuji, Yasunori Ueda, Masataka Okamoto, Yasushi Terasaki, Naoko Tsuyama, Kosei Matsue, Tomohiro Kinoshita, Go Yamamoto, Shuichi Taniguchi, Shigeru Chiba, Koichi Ohshima, Koji Izutsu

Blood Adv (2020) 4 (18): 4442–4450.

https://doi.org/10.1182/bloodadvances.2020002293

Published: 2020

Includes: Supplemental data

Journal Articles

Fractures are common within 18 months following first-line R-CHOP in older patients with diffuse large B-cell lymphoma

Blood Adv (2020) 4 (18): 4337–4346.

https://doi.org/10.1182/bloodadvances.2020002553

Published: 2020

Includes: Supplemental data

Journal Articles

Ibrutinib added to 10-day decitabine for older patients with AML and higher risk MDS

Blood Adv (2020) 4 (18): 4267–4277.

https://doi.org/10.1182/bloodadvances.2020002846

Published: 2020

Includes: Supplemental data

Journal Articles

American Society of Hematology 2020 guidelines for treating newly diagnosed acute myeloid leukemia in older adults

Blood Adv (2020) 4 (15): 3528–3549.

https://doi.org/10.1182/bloodadvances.2020001920

Published: 2020

Includes: Supplemental data

Journal Articles

High-dose chemotherapy and autologous stem cell transplant in elderly patients with primary CNS lymphoma: a pilot study

Elisabeth Schorb, Benjamin Kasenda, Gabriele Ihorst, Florian Scherer, Julia Wendler, Lisa Isbell, Heidi Fricker, Juergen Finke, Gerald Illerhaus

Blood Adv (2020) 4 (14): 3378–3381.

https://doi.org/10.1182/bloodadvances.2020002064

Published: 2020

Includes: Supplemental data

Journal Articles

Nationwide survey of systemic chronic active EBV infection in Japan in accordance with the new WHO classification

Ichiro Yonese, Chizuko Sakashita, Ken-Ichi Imadome, Tohru Kobayashi, Masahide Yamamoto, Akihisa Sawada, Yoshinori Ito, Noriko Fukuhara, Asao Hirose, Yusuke Takeda, Masanori Makita, Tomoyuki Endo, Shun-ichi Kimura, Masataka Ishimura, Osamu Miura, Shouichi Ohga, Hiroshi Kimura, Shigeyoshi Fujiwara, Ayako Arai

Blood Adv (2020) 4 (13): 2918–2926.

https://doi.org/10.1182/bloodadvances.2020001451

Published: 2020

Includes: Supplemental data

Journal Articles

Clinical outcomes of older patients with AML receiving hypomethylating agents: a large population-based study in the United States

Amer M. Zeidan, Rong Wang, Xiaoyi Wang, Rory M. Shallis, Nikolai A. Podoltsev, Jan P. Bewersdorf, Scott F. Huntington, Natalia Neparidze, Smith Giri, Steven D. Gore, Amy J. Davidoff, Xiaomei Ma

Blood Adv (2020) 4 (10): 2192–2201.

https://doi.org/10.1182/bloodadvances.2020001779

Published: 2020

Includes: Supplemental data

Journal Articles

Added prognostic value of secondary AML-like gene mutations in ELN intermediate-risk older AML: ALFA-1200 study results

Blood Adv (2020) 4 (9): 1942–1949.

https://doi.org/10.1182/bloodadvances.2019001349

Published: 2020

Includes: Supplemental data

Journal Articles

Outcomes of older patients with NPM1-mutated AML: current treatments and the promise of venetoclax-based regimens

Blood Adv (2020) 4 (7): 1311–1320.

https://doi.org/10.1182/bloodadvances.2019001267

Published: 2020

Includes: Supplemental data

Journal Articles

Anthracycline-related cardiotoxicity in older patients with acute myeloid leukemia: a Young SIOG review paper

Nina Rosa Neuendorff, Kah Poh Loh, Alice S. Mims, Konstantinos Christofyllakis, Wee-Kheng Soo, Bediha Bölükbasi, Carlos Oñoro-Algar, William G. Hundley, Heidi D. Klepin

Blood Adv (2020) 4 (4): 762–775.

https://doi.org/10.1182/bloodadvances.2019000955

Published: 2020

Journal Articles

Combination of dasatinib with chemotherapy in previously untreated core binding factor acute myeloid leukemia: CALGB 10801

Guido Marcucci, Susan Geyer, Kristina Laumann, Weiqiang Zhao, Donna Bucci, Geoffrey L. Uy, William Blum, Ann-Kathrin Eisfeld, Timothy S. Pardee, Eunice S. Wang, Wendy Stock, Jonathan E. Kolitz, Jessica Kohlschmidt, Krzysztof Mrózek, Clara D. Bloomfield, Richard M. Stone, Richard A. Larson

Blood Adv (2020) 4 (4): 696–705.

https://doi.org/10.1182/bloodadvances.2019000492

Published: 2020

Journal Articles

A phase 1 study of azacitidine with high-dose cytarabine and mitoxantrone in high-risk acute myeloid leukemia

Kirk E. Cahill, Yasmin H. Karimi, Theodore G. Karrison, Nitin Jain, Margaret Green, Howard Weiner, Noreen Fulton, Sabah Kadri, Lucy A. Godley, Andrew S. Artz, Hongtao Liu, Michael J. Thirman, Michelle M. Le Beau, Megan E. McNerney, Jeremy Segal, Richard A. Larson, Wendy Stock, Olatoyosi Odenike

Blood Adv (2020) 4 (4): 599–606.

https://doi.org/10.1182/bloodadvances.2019000795

Published: 2020

Includes: Supplemental data

Journal Articles

BST-236, a novel cytarabine prodrug for patients with acute leukemia unfit for standard induction: a phase 1/2a study

Tsila Zuckerman, Ron Ram, Luiza Akria, Maya Koren-Michowitz, Ron Hoffman, Israel Henig, Noa Lavi, Yishai Ofran, Netanel A. Horowitz, Olga Nudelman, Sigal Tavor, Shay Yeganeh, Stela Gengrinovitch, Liat Flaishon, Shoshi Tessler, Ruth Ben Yakar, Jacob M. Rowe

Blood Adv (2019) 3 (22): 3740–3749.

https://doi.org/10.1182/bloodadvances.2019000468

Published: 2019

Includes: Supplemental data

NARROW

Multicenter analysis of geriatric fitness and real-world outcomes in older patients with classical Hodgkin lymphoma

Toxicities of high-dose chemotherapy and autologous hematopoietic cell transplantation in older patients with lymphoma

Impact of R-CHOP dose intensity on survival outcomes in diffuse large B-cell lymphoma: a systematic review

Infection-related morbidity and mortality among older patients with DLBCL treated with full- or attenuated-dose R-CHOP

Outcomes of older patients with follicular lymphoma using individual data from 5922 patients in 18 randomized controlled trials

Older adults with newly diagnosed high-risk/secondary AML who achieved remission with CPX-351: phase 3 post hoc analyses

Measurable residual disease in elderly acute myeloid leukemia: results from the PETHEMA-FLUGAZA phase 3 clinical trial

Primary human herpesvirus 8–negative effusion-based lymphoma: a large B-cell lymphoma with favorable prognosis

Fractures are common within 18 months following first-line R-CHOP in older patients with diffuse large B-cell lymphoma

Ibrutinib added to 10-day decitabine for older patients with AML and higher risk MDS

American Society of Hematology 2020 guidelines for treating newly diagnosed acute myeloid leukemia in older adults

High-dose chemotherapy and autologous stem cell transplant in elderly patients with primary CNS lymphoma: a pilot study

Nationwide survey of systemic chronic active EBV infection in Japan in accordance with the new WHO classification

Clinical outcomes of older patients with AML receiving hypomethylating agents: a large population-based study in the United States

Added prognostic value of secondary AML-like gene mutations in ELN intermediate-risk older AML: ALFA-1200 study results

Outcomes of older patients with NPM1-mutated AML: current treatments and the promise of venetoclax-based regimens

Anthracycline-related cardiotoxicity in older patients with acute myeloid leukemia: a Young SIOG review paper

Combination of dasatinib with chemotherapy in previously untreated core binding factor acute myeloid leukemia: CALGB 10801

A phase 1 study of azacitidine with high-dose cytarabine and mitoxantrone in high-risk acute myeloid leukemia

BST-236, a novel cytarabine prodrug for patients with acute leukemia unfit for standard induction: a phase 1/2a study

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only